ATGL-1 mediates the effect of dietary restriction and the insulin/IGF-1 signaling pathway on longevity in C
Other common side effects reported in 5% or more of people in clinical trials include: Digestive system Indigestion (dyspepsia) Abdominal pain or upper abdominal pain Gastroenteritis (stomach bug) Increased lipase levels (a pancreatic enzyme, detected on blood tests) General Headache Fatigue (feeling tired) Dizziness Fever Other Injection site reactions such as redness, irritation, or bruising Low blood sugar (hypoglycemia), particularly if you also take insulin or a sulfonylurea Contact your doctor if any side effects are severe, persistent, or affecting your daily life
Systemic clearance of p16 -positive senescent cells mitigates age-associated intervertebral disc degeneration
Plans commonly use prior authorization, BMI thresholds, medical necessity review, documentation of weight-related conditions, and evidence of previous weight loss efforts for both medications
However, real-world data shows conflicting persistence trends, with one study revealing that 63% of patients persist for at least one year, while another shows that one-third of people stopped taking their GLP-1 in the first month, and less than half stayed on for more than 12 weeks
.png)
